Shushan Rana, MD
Radiation Oncology · Vancouver, WANPI 1487091260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Raysearch Laboratories AB (publ) accounts for 65.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $485 and has fallen 93.3% since, to $33 in 2025.
Across 10 payments — averaging $74.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Raysearch Laboratories AB (publ)$485
- Viewray Technologies Inc$97
- Teleflex LLC$35
- Novartis$34
- AstraZeneca$33
- Boston Scientific$18
- plus $45 from 3 others
What the payments were for
- Food & beverage$746100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Raysearch Laboratories AB (publ) | 1 | $485 |
| Viewray Technologies Inc | 2 | $97 |
| Teleflex LLC | 1 | $35 |
| Novartis | 1 | $34 |
| AstraZeneca | 1 | $33 |
| Boston Scientific | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Progenics Pharmaceuticals, Inc. | 1 | $15 |
| Varian Medical Systems, Inc. | 1 | $14 |
How this compares
$746 in reported general payments places this provider in the 65th percentile of 168 radiation oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trazodone Hcl | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Vancouver
- Scott SchneiderVancouver$9K
- Stephen HoffeltVancouver$2K
- Faisal SiddiquiVancouver$656
- Christopher LeeSpokane Valley$138K
- Vivek MehtaSeattle$120K
- Christopher LoiselleSeattle$63K
- Ramesh RenganSeattle$57K
- Jing ZengSeattle$37K
- Omar MianSeattle$22K
- Susan GuoTacoma$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.